The U.S. Food and Drug Administration (FDA) granted approval for Liraglutide (ANDA 218115) on April 2, 2025. This approval signifies the availability of a generic version of the drug, with NANJING KING FRIEND listed as the sponsor.
Background
Liraglutide is the generic name for a drug that has existing approved formulations on the market. An Abbreviated New Drug Application (ANDA) approval, such as this one for ANDA 218115, is the process by which the FDA approves generic versions of previously approved brand-name drugs. This pathway allows generic manufacturers to demonstrate that their product is bioequivalent to the reference listed drug (RLD), without having to repeat the extensive clinical trials that were required for the original brand-name drug. The approval confirms that the generic Liraglutide is therapeutically equivalent to its brand-name counterpart, ensuring it can be substituted with the expectation that it will produce the same clinical effect and safety profile when administered to patients.
What this means
The FDA approval of Liraglutide as a generic drug (ANDA 218115) marks a significant milestone for patients and the healthcare system. Generic drugs are rigorously evaluated by the FDA to ensure they are bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient, are identical in strength, dosage form, and route of administration, and are absorbed into the bloodstream at the same rate and to the same extent. This ensures that generic versions work in the same way and provide the same clinical benefit as the original drug.
The introduction of generic alternatives typically leads to increased market competition, which can drive down prescription drug costs. This can make essential medications more accessible and affordable for a broader patient population, reducing financial burdens on individuals and healthcare payers. The approval allows NANJING KING FRIEND to manufacture and market its generic version of Liraglutide, contributing to the availability of cost-effective treatment options.
Source
This information is based on an initial FDA approval for Liraglutide (ANDA 218115) issued by the U.S. Food and Drug Administration on April 2, 2025, as documented on accessdata.fda.gov.